EX

Exelixis

Every trial this sponsor leads in the registry, and everything it has published.

55All trials
Recruiting8
Recruited10
Not yet recruiting2
By invitation1
Completed18
Stopped16

21 active · 38% of this sponsor’s registry footprint

Oncology19 trials
Gastroenterology & Hepatology1 trial

Not shown above: 1 trial whose condition matched no therapy area.

Trials by phase

Phase 133
Phase 28
Phase 313
Phase 41

Pipeline by phase · 7 drugs in active development

Phase 3 · 2 drugs

Zanzalintinib (XL092)10 trials · 4 recruitingest. Dec 2026
cabozantinib6 trialsest. May 2030

Phase 1 · 4 drugs

XB0101 trial · 1 recruitingest. Nov 2026
XB3711 trial · 1 recruitingest. Nov 2027
XB6281 trial · 1 recruitingest. May 2027
XL3091 trial · 1 recruitingest. Jan 2029

Phase 4 · 1 drug

Active trials only, code names and brands merged. 18 completed trials are in the counts above but their drugs are not folded into this pipeline.

Disease landscapes · 2 of 10 curated

Breast cancer (Oncology)3 trials · 2 recruiting · 3 drugs0.1% of landscape
Non-small cell lung cancer (Oncology)3 trials · 2 recruiting · 3 drugs0.2% of landscape

Active trials judged against ten curated disease boundaries; the share compares this company's active trials with the landscape's industry-wide total. Activity outside these landscapes appears in the therapy-area split above.

Track your drug now for free

We check every one of its trials daily and tell you what moved.

  • Status changeStatus moved to completedWas recruiting · always alerts
  • Completion date movePrimary completion slipped 210 daysSlips and pull-ins of 30+ days
  • New trialNew trial registered in your scopeFirst posted within 30 days
  • Enrollment changeEnrollment grew to 1,200Moves of 15%+ or count finalised
  • Substantive record editPrimary endpoint redefined from 24 to 52 weeksRead overnight and flagged in plain English
US registryClinicalTrials.gov
EU registryCTIS · Soon